Repositioning Candidate Details
| Candidate ID: | R0033 |
| Source ID: | DB00160 |
| Source Type: | nutraceutical |
| Compound Type: | small molecule |
| Compound Name: | Alanine |
| Synonyms: | |
| Molecular Formula: | C3H7NO2 |
| SMILES: | C[C@H](N)C(O)=O |
| Structure: |
|
| DrugBank Description: | Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. |
| CAS Number: | 56-41-7 |
| Molecular Weight: | 89.0932 |
| DrugBank Indication: | Used for protein synthesis. |
| DrugBank Pharmacology: | Is an important source of energy for muscle tissue, the brain and central nervous system; strengthens the immune system by producing antibodies; helps in the metabolism of sugars and organic acids. |
| DrugBank MoA: | L-Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. BCAAs are used as a source of energy for muscle cells. During prolonged exercise, BCAAs are released from skeletal muscles and their carbon backbones are used as fuel, while their nitrogen portion is used to form another amino acid, Alanine. Alanine is then converted to Glucose by the liver. This form of energy production is called the Alanine-Glucose cycle, and it plays a major role in maintaining the body's blood sugar balance. |
| Targets: | Serine--pyruvate aminotransferase; Alanine aminotransferase 1; Cysteine desulfurase, mitochondrial; Proton-coupled amino acid transporter 1; Large neutral amino acids transporter small subunit 2; Alanine--glyoxylate aminotransferase 2, mitochondrial; Alanine--tRNA ligase, cytoplasmic; Neutral amino acid transporter A; 4-aminobutyrate aminotransferase, mitochondrial; Kynureninase; Alanine--tRNA ligase, mitochondrial; 5-phosphohydroxy-L-lysine phospho-lyase; Alanine aminotransferase 2 |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |